Used as a key intermediate in the synthesis of tyrosine kinase inhibitors, particularly in the development of anticancer agents. It plays a critical role in targeting epidermal growth factor receptor (EGFR) mutations, making it valuable in treatments for non-small cell lung cancer (NSCLC). The compound's structure allows for selective binding and improved pharmacokinetic properties in final drug formulations. It is primarily utilized in pharmaceutical research and development for creating targeted therapies with reduced side effects.